Erlotinib Completed Phase 1 Trials for Stage III Verrucous Carcinoma of the Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVC Verrucous Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Larynx / Tongue Cancer / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Untreated Metastatic Squamous Neck Cancer With Occult Primary / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Larynx Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00049283Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer